Kangtai Bio launches phase III trial for rotavirus vaccine

Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601), and its subsidiary Beijing Minhai Biotechnology, have announced the commencement of Phase III clinical trials for their oral pentavalent reassortant rotavirus live attenuated vaccine (Vero cells). The trial, designed as a multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the vaccine's protective efficacy, safety, and immunogenicity in infants in China aged 6 to 32 weeks. This vaccine targets the G1, G2, G3, G4, and G9 serotypes of rotavirus. The successful development of this vaccine will enrich the company's product portfolio in the multivalent vaccine area, enhancing its market competitiveness. Kangtai Bio cautions that the development of vaccines has uncertainty.